Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04561518 · ClinicalTrials.gov registry record
ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
A clinical trial of ATTR Amyloidosis and Transthyretin-Mediated Amyloidosis, sponsored by Alnylam Pharmaceuticals.
- Recruiting
- Registry status
- 1,500
- Enrollment target
- 20
- Study locations
NCT04561518: Recruiting study of ATTR Amyloidosis and Transthyretin-Mediated Amyloidosis, sponsored by Alnylam Pharmaceuticals.
NCT04561518 is a study of ATTR Amyloidosis and Transthyretin-Mediated Amyloidosis that is actively recruiting participants, run by Alnylam Pharmaceuticals. The registered enrollment target is 1,500 participants. The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04561518, a study of ATTR Amyloidosis and Transthyretin-Mediated Amyloidosis, is actively recruiting participants, sponsored by Alnylam Pharmaceuticals.
- RECRUITING
- Registry status
- 1,500 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to: * Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients * Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world clinical setting * Describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) variant
Conditions Studied
Study Locations (20)
Other
- Clinical Trial Site - Salvador
- Clinical Trial Site - São Paulo
- Clinical Trial Site - Sofia
- Clinical Trial Site - Aarhus
- Clinical Trial Site - Copenhagen
- Clinical Trial Site - Bordeaux
- Clinical Trial Site - Bron
California
- Clinical Trial Site - La Jolla
- Clinical Trial Site - Los Angeles
Texas
- Clinical Trial Site - Austin
- Clinical Trial Site - Houston
Florida
- Clinical Trial Site - Jacksonville
Iowa
- Clinical Trial Site - Iowa City
Kansas
- Clinical Trial Site - Kansas City
Maryland
- Clinical Trial Site - Baltimore
Massachusetts
- Clinical Trial Site - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2020-11-23 |
| Est. Completion | 2030-09-01 |
What NCT04561518 shows while recruiting
NCT04561518 is an observational study that tracks outcomes without assigning an intervention. Its 1,500 participants enrollment target places it among the larger protocols in the corpus.
The record links to 2 conditions, with ATTR Amyloidosis appearing as the primary indexed condition, and to 0 interventions.
NCT04561518 names 20 study sites across 12 states, led by Other, California, Texas.
Frequently Asked Questions
What is clinical trial NCT04561518 about?
NCT04561518 is a clinical study titled "ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)". The purpose of this study is to: * Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients * Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world cl...
What is the current status of trial NCT04561518?
This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2020-11-23. Estimated completion is 2030-09-01.
What conditions does trial NCT04561518 study?
This clinical trial studies the following conditions: ATTR Amyloidosis, Transthyretin-Mediated Amyloidosis.
Who is sponsoring clinical trial NCT04561518?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04561518 being conducted?
This trial has 20 study locations across California, Florida, Iowa, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ATTR Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI